Literature DB >> 3265314

Interleukin-2 differentially affects the proliferation of a hormone-dependent and a hormone-independent human breast cancer cell line in vitro and in vivo.

G F Paciotti1, L Tamarkin.   

Abstract

Direct in vitro and in vivo effects of the lymphokine, interleukin-2 (IL-2), on hormone-dependent (MCF-7) and- independent (MDA-231) human breast cancer cell proliferation were investigated. In vitro, picomolar concentrations of IL-2 directly inhibited MCF-7 cell proliferation after 12 days of culture, while nanomolar doses of IL-2 significantly stimulated MCF-7 cell growth over the same time period. In addition, micromolar concentrations of IL-2 had virtually no effect on the in vitro proliferation of MCF-7 cells. In parallel in vitro growth experiments, the hormone-independent cells, MDA-231, were not affected by IL-2 regardless of concentration. IL-2 treatment of overiectomized, estrogen-treated nude mice, burdened with MCF-7 or MDA-231 tumors, inhibited MCF-7 tumor growth, but had no effect on MDA-231 tumors. Examination of T, B and natural killer (NK) cell function in these animals indicated that the interleukin-2-mediated effect on MCF-7 cell growth in vivo is independent of the proliferative abilities of these lymphoid cells, suggesting that IL-2 may directly affect the growth of these hormone-dependent human breast cancer cells.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3265314

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  6 in total

1.  Neuronal-glial interactions mediated by interleukin-1 enhance neuronal acetylcholinesterase activity and mRNA expression.

Authors:  Y Li; L Liu; J Kang; J G Sheng; S W Barger; R E Mrak; W S Griffin
Journal:  J Neurosci       Date:  2000-01-01       Impact factor: 6.167

2.  Local Interleukin-2 Immunotherapy of Breast Cancer: Benefit and Risk in a Spontaneous Mouse Model.

Authors:  Svetlana G Semushina; Dmitry A Aronov; Ekaterina V Moiseeva
Journal:  Pathol Oncol Res       Date:  2018-03-06       Impact factor: 3.201

3.  Increased proliferation of a human breast carcinoma cell line by recombinant interleukin-2.

Authors:  M Katano; T Matsuo; T Morisaki; K Naito; F Nagumo; E Kubota; M Nakamura; T Hisatsugu; J Tadano
Journal:  Cancer Immunol Immunother       Date:  1994-09       Impact factor: 6.968

4.  Subcutaneously administered recombinant human interleukin-2 and interferon alfa-2a for advanced breast cancer: a phase II study of the Cancer and Leukemia Group B (CALGB 9041).

Authors:  Gretchen Kimmick; Mark J Ratain; Don Berry; Susan Woolf; Larry Norton; Hyman B Muss
Journal:  Invest New Drugs       Date:  2004-01       Impact factor: 3.850

5.  Growth of MCF-7 human breast carcinoma in severe combined immunodeficient mice: growth suppression by recombinant interleukin-2 treatment and role of lymphokine-activated killer cells.

Authors:  Y F Zhai; W J Esselman; C S Oakley; C C Chang; C W Welsch
Journal:  Cancer Immunol Immunother       Date:  1992       Impact factor: 6.968

6.  TMEM115 is an integral membrane protein of the Golgi complex involved in retrograde transport.

Authors:  Yan Shan Ong; Ton Hoai Thi Tran; Natalia V Gounko; Wanjin Hong
Journal:  J Cell Sci       Date:  2014-05-07       Impact factor: 5.285

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.